Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response - 18/02/12
Abstract |
Current topical agents for field therapy of actinic keratoses have single mechanisms of action and must be applied for weeks. Ingenol mebutate gel, a novel drug for field therapy of actinic keratoses, appears to have a dual mechanism of action: (1) rapid lesion necrosis and (2) specific neutrophil-mediated, antibody-dependent cellular cytotoxicity. Because of the rapid destruction of actinic keratosis lesions after application of ingenol mebutate gel, treatment is necessary for only 2 or 3 days. The subsequent immune-mediated response targets any residual dysplastic epidermal cells. This dual mechanism of action should provide efficacy equivalent to that of current topical agents with a substantially shorter treatment period.
Le texte complet de cet article est disponible en PDF.Key words : actinic keratosis, ingenol mebutate gel, mechanism of action, neutrophil, neutrophil-mediated antibody-dependent cellular cytotoxicity, protein kinase C, rapid lesion necrosis
Abbreviations used : ADCC, AK, MOA
Plan
Funding sources: None. |
|
Disclosure: Within the past 5 years, Dr Rosen has served as a consultant, speaker, and investigator for LEO Pharma and for Allergan, for which he has received honoraria; for Galderma and Novartis, he served as consultant and investigator, for which he received honoraria. In the past 5 years, Dr Tyring has received grants and honoraria for his work on behalf of GlaxoSmithKline, Novartis, Merck, Amgen, Abbott, and Graceway as, variously, a consultant, investigator, and speaker; grants and honoraria from Galderma for his work as an investigator; honoraria from Warner Chilcott for his work as a speaker; grants and honoraria from Astellas, Inhibitex, and Stiefel for his work as a consultant and investigator; and grants from Eli Lilly and Company and LEO Pharma for his work as an investigator. Dr Gupta has no conflict of interest to declare. |
Vol 66 - N° 3
P. 486-493 - mars 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?